Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Canada Pension Plan Investment Board ","pharmaFlowCategory":"D","amount":"$80.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sigilon Therapeutics Announces $80.3 Million Series B Financing to Advance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chronic Disease Biotech Sigilon Therapeutics Files for a $100 Million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigilon Preclinical Data International Symposium on MPS and Related Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium\u2122 on Lysosomal Diseases, MPS-1 and MPS-6","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$344.2 million","upfrontCash":"$344.2 million","newsHeadline":"Lilly to Acquire Sigilon Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$344.2 million","upfrontCash":"$344.2 million","newsHeadline":"Lilly Completes Acquisition of Sigilon Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sigilon Therapeutics

    Menu

    Sigilon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sigilon Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly Completes Acquisition of Sigilon Therapeutics

              Details:

              Through the acquisition, Lilly gains control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.

              Lead Product(s): SIG-002

              Therapeutic Area: Endocrinology Product Name: SIG-002

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $344.2 million Upfront Cash: $344.2 million

              Deal Type: Acquisition August 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sigilon Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly to Acquire Sigilon Therapeutics

              Details:

              Through the acquisition, Lilly will gain control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.

              Lead Product(s): Insulin Lispro

              Therapeutic Area: Endocrinology Product Name: SIG-002

              Highest Development Status: Discovery Product Type: Peptide

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $344.2 million Upfront Cash: $344.2 million

              Deal Type: Acquisition June 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sigilon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6

              Details:

              SIG-005 contains a human cell line genetically modified with a non-viral vector designed to express human a-L-iduronidase (IDUA), an enzyme which is missing or defective in patients with MPS-1.

              Lead Product(s): SIG-005

              Therapeutic Area: Genetic Disease Product Name: SIG-005

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sigilon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sigilon Preclinical Data International Symposium on MPS and Related Diseases

              Details:

              Sigilon recently filed a Clinical Trial Application (CTA) in the United Kingdom for SIG-005 in MPS-1 and anticipates submitting an Investigational New Drug (IND) application and a CTA in the United States and Brazil, respectively.

              Lead Product(s): SIG-005

              Therapeutic Area: Genetic Disease Product Name: SIG-005

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sigilon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

              Details:

              SIG-005 contains a human cell line genetically modified with a non-viral vector designed to express human a-L-iduronidase (IDUA), an enzyme which is missing or defective in patients with MPS-1.

              Lead Product(s): SIG-005

              Therapeutic Area: Genetic Disease Product Name: SIG-005

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sigilon Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chronic Disease Biotech Sigilon Therapeutics Files for a $100 Million IPO

              Details:

              Sigilon's lead candidate, SIG-001, is designed to prevent bleeding episodes in patients with Hemophilia A and recently began a Phase 1/2 trial.

              Lead Product(s): SIG-001

              Therapeutic Area: Genetic Disease Product Name: SIG-001

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Morgan Stanley

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering November 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sigilon Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sigilon Therapeutics Announces $80.3 Million Series B Financing to Advance

              Details:

              The funding will support the first-in-human clinical trial of Sigilon’s novel encapsulated cell therapy for hemophilia A.

              Lead Product(s): SIG-001

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Canada Pension Plan Investment Board

              Deal Size: $80.3 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing March 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY